The mRNA Mirage: How a Single Stock's Surge Masks Broader Industry Woes August has been a month of great excitement for investors, with Merck & Co. , Inc. 's (NYSE:MRK) 12. 6% surge and Moderna Inc.
's (NASDAQ:MRNA) 176% explosion capturing headlines. However, beneath the surface lies a more nuanced story. The trial results announced by Moderna Inc. in collaboration with Merck & Co. , Inc.
demonstrate the potential of combining MRNA based vaccines with established cancer therapies like Keytruda.